Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumabHagström, Emil; Steg, P. Gabriel; Szarek, Michael; Bhatt, Deepak L.; Bittner, Vera A.; Danchin, Nicolas; Diaz, Rafael; Goodman, Shaun G.; Harrington, Robert A.; Jukema, J. Wouter; Liberopoulos, Evangelos; Marx, Nikolaus; Viigimaa, MargusCirculation2022 / p. 657 - 672 https://doi.org/10.1161/CIRCULATIONAHA.121.057807 Journal metrics at Scopus Article at Scopus Journal metrics at WOS Article at WOS

Lipoprotein(a) and Benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterolSchwartz, Gregory G.; Szarek, Michael; Bittner, Vera A.; Diaz, Rafael; Goodman, Shaun G.; Viigimaa, MargusJournal of the American College of Cardiology2021 / p. 421–433 : ill https://www.jacc.org/doi/epdf/10.1016/j.jacc.2021.04.102 https://doi.org/10.1016/j.jacc.2021.04.102

2022: The year in cardiovascular disease - the year of upfront lipid lowering combination therapyBanach, Maciej; Reiner, Zeljko; Cicero, Arrigo F.G.; Sabouret, Pierre; Viigimaa, Margus; Sahebkar, Amirhossein; Postadzhiyan, Arman; Gaita, Dan; Pella, Daniel; Penson, Peter E.Archives of Medical Science2022 / p. 1429-1434 : ill https://doi.org/10.5114/aoms/156147 Journal metrics at Scopus Article at Scopus Journal metrics at WOS Article at WOS